<DOC>
	<DOCNO>NCT00418431</DOCNO>
	<brief_summary>Central serous chorioretinopathy ( CSC ) know since first describe Von Graefe term “ idiopathic detachment macula ” 1866 , well-characterized disorder lead serous neurosensory elevation central macula . The acute form disease associate focal leakage level retinal pigment epithelium ( RPE ) demonstrate fluorescein angiography ( FA ) . The disorder self-limited majority patient , also regain excellent vision . Occasionally , neurosensory detachment persist lead pigment epithelial photoreceptor damage visual impairment . The purpose clinical study report use intravitreal bevacizumab new option treatment chronic recurrent CSC .</brief_summary>
	<brief_title>Intravitreal Bevacizumab Treatment Central Serous Chorioretinopathy</brief_title>
	<detailed_description />
	<mesh_term>Central Serous Chorioretinopathy</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Inclusion Criteria Any visual acuity . Central serous chorioretinopathy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2006</verification_date>
</DOC>